| Document |
Document Title |
|
WO/1995/010504A1 |
Compounds of formula (I), wherein R1 represents C1-4alkyl; R2 represents hydrogen, halogen, C1-4alkyl, C1-4alkoxy, C1-4alkoxyC1-4alkyl, C1-4alkylsulphonyl, trifluoromethylsulphonyl; optionally substituted arylsulphonyl, optionally substi...
|
|
WO/1995/005805A1 |
The present invention relates to a process for providing a stable crystallinic form to a fine-grained substance or a substance mixture, which can be produced, stored and used while maintaining the aerodynamic properties required for inha...
|
|
WO/1995/004955A1 |
A colored composition which includes a colorant and an ultraviolet radiation transorber. The colorant, in the presence of the ultraviolet radiation transorber, is adapted, upon exposure of the transorber to ultraviolet radiation, to be m...
|
|
WO/1995/004036A1 |
Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to membe...
|
|
WO/1995/004277A1 |
Methods for rapidly generating large rationally designed libraries of structurally-diverse small molecular weight compounds using a multicombinatorial approach. Also disclosed are compounds of formula (I).
|
|
WO/1995/003266A1 |
Therapeutic compositions comprising 1,8-dihydroxy-9(10H) anthracenones substituted at position 10 thereof with phenylalkylidene or arylacyl blocking moieties, said compounds having substantial therapeutic activity and minimal inflammator...
|
|
WO/1995/003295A1 |
Novel derivatives of general structural formula (I) have endothelin antagonist activity and are therefore useful in treating cardiovascular disorders, such as hypertension, pulmonary hypertension, postischemic renal failure, vasospasm, c...
|
|
WO/1995/000468A1 |
The present invention provides novel fluorenone derivatives represented by formula (A) (wherein Ra-Rg are defined in the specification), and a method for repairing and protecting central or peripheral nerve degeneration comprising use of...
|
|
WO/1994/026726A1 |
Novel 1,2-dioxetanes with improved chemiluminescent properties, such as signal intensity, S/N ratio, T1/2, etc. are provided by spiroadamantyl 1,2-dioxetanes, wherein the remaining carbon atom of the ring bears an alkoxy, aryloxy, or ary...
|
|
WO/1994/025547A1 |
A new lubricant comprises at least one compound having a perfluorocyclobutane group, preferably a perfluorovinyl aryl ether. The lubricant is conveniently applied from solvents which are not chlorofluorocarbons and is effective at high t...
|
|
WO/1994/025460A1 |
A compound which is a pamoate acid addition salt of risperidone, compositions comprising the same and processes for preparing said compound and compositions.
|
|
WO/1994/025505A1 |
Polyimides are prepared by (a) contacting monomers which are oligomers having at least one imide group or imide precursor group and at least two dimerizable perfluorovinyl end groups, and (b) exposing the monomers to a temperature of at ...
|
|
WO/1994/021590A1 |
Phenoxyphenylacetic acids and derivatives of general structural formula (I) have endothelin antagonist activity and are useful in treating cardiovascular disorders, such as hypertension, postischemic renal failure, vasospasm, cerebral an...
|
|
WO/1994/021591A1 |
A dermatologic preparation containing at least one of the benzoic acid derivatives represented by general formula (I) and pharmacologically acceptable salts thereof, having a sufficient effect of inhibiting sebum secretion and being free...
|
|
WO/1994/019437A1 |
A composition of matter useful in lubricating oil for reducing friction in an internal combustion engine, said complex comprising the reaction product of alkoxylated amine, acid and adenine and having formula (I), wherein Z is derived fr...
|
|
WO/1994/015901A1 |
Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to membe...
|
|
WO/1994/015902A1 |
Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to membe...
|
|
WO/1994/015258A1 |
A polymer has at least one photoactive site and more than one perfluorocyclobutane group. New monomers containing photoactive sites or photoactive precursors and at least one perfluorovinyl group are useful for making such polymers. Proc...
|
|
WO/1994/014750A1 |
There is provided a novel salicylic acid derivative of formula (I), wherein R means hydrogen or a C1-4alkyl group; R1 stands for hydroxy; a C1-4alkoxy group; or a group of formula (A), wherein R2 means hydrogen or benzyl group; and R3 st...
|
|
WO/1994/014800A1 |
Compounds of general formula (1) are described, wherein Y is a halogen atom or a group -OR1, wherein R1 is an optionally substituted alkyl group; X is -O-, -S- or -N(R6)-, where R6 is a hydrogen atom or an alkyl group; R2 is an optionall...
|
|
WO/1994/014742A1 |
Compounds of general formula (1) are described wherein Y is a halogen atom or a group -OR1, where R1 is an optionally substituted alkyl group; X is -O-, -S- or -N(R8)-, where R8 is a hydrogen atom or an alkyl group; R2 is an optionally s...
|
|
WO/1994/013666A1 |
The invention provides an industrially excellent process for producing a 2-alkyl-3-(biphenyl-4-yl)-methyl-3H-imidazo[4.5-b]pyridine derivative represented by general formula (II), serving as a precursor of the angiotensin II receptor ant...
|
|
WO/1994/012461A1 |
This invention relates to 4-substituted catechol diether compounds which are selective inhibitors of phosphodiesterase (PDE) type IV. The compounds of the present invention are useful in inhibiting PDEIV and in the treatment of AIDS, ast...
|
|
WO/1994/012880A2 |
The invention provides a method of screening a substance for the ability to affect the formation of a retinoid X receptor homodimer comprising combining the substance and a solution containing retinoid X receptors and determining the pre...
|
|
WO/1994/007838A1 |
An isocarbacyclin with the alpha-chain modified with phenylene, cycloalkylene or thiophenediyl. It has the activity of inhibiting DNA synthesis of human smooth muscle cells and is expected to inhibit vascular hypertrophy.
|
|
WO/1994/005621A1 |
A novel process for the manufacture of a cinnamic acid derivative of formula (I) wherein R1 signifies hydrogen or C1-8-alkyl and R2 signifies hydrogen, C1-10-alkyl, C1-10-hydroxyalkyl or C1-4-hydroxyalkyl or C1-4-alkoxy-C1-10-alkyl, is d...
|
|
WO/1994/004522A1 |
Antagonists of the leukotrienes-B4 have formula (I), in which n is an integer between 2 and 5, X is a direct bond, 1 to 6 methylene units, an ortho-, meta- or para-substituted phenyl ring or a meta- or para-substituted pyridin ring; Y is...
|
|
WO/1994/003165A1 |
A method of inhibiting thrombus formation in mammalian subject. The method involves administering to the subject a therapeutically effective dose of a calix(n)arene compound derivatized, at its ring positions meta to the bridge attachmen...
|
|
WO/1994/003164A1 |
A method for inhibiting cell infection by an enveloped virus, by administering to an infection site, a therapeutically effective amount of a calix(n) arene compound derivatized, at its ring positions meta to the bridge attachments to the...
|
|
WO/1994/002465A1 |
This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation an...
|
|
WO/1994/001436A1 |
The invention provides compounds of formula (I), and pharmaceutically acceptable salts thereof; wherein R50 is hydrogen or C1-4 alkyl, A51 is oxygen, sulphur or a group of the formula -NR52- wherein R52 is hydrogen or C1-4 alkyl; A50 com...
|
|
WO/1993/025530A2 |
A process and pharmaceutical compositions for treating several diseases and conditions which are normally treatable with retinoid-like compounds are disclosed where the compounds used for the treatment are substantially non-teratogenic a...
|
|
WO/1993/023357A1 |
The present invention relates to stilbene derivatives which possess utility as anti-cancer agents. The compounds can be used to treat cancers which are susceptible to treatment therewith, and can be utilized in a method of treating such ...
|
|
WO/1993/021772A2 |
Herbicidal composition comprising N-[2-(3,3,3-trifluoropropyl)-phenylsulfonyl]-N'-(4-methoxy-6
-methyl-1,3,5-triazin-2-yl)-urea of formula (I) or agrochemically tolerated salts thereof, and a synergistic amount of one or more further her...
|
|
WO/1993/021195A1 |
The invention relates to novel water-soluble sugar retinoids (I) in which the sugar radical carries at least one sulfate group, and to their preparation and the use thereof as medicaments and in the cosmetic sector. In formula (I), X is ...
|
|
WO/1993/021146A1 |
Compounds, compositions, and method for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to member...
|
|
WO/1993/016970A1 |
A method of separating isomers of functionalized aromatic compounds using solvent-modified supercritical carbon dioxide is disclosed and claimed. In one embodiment, isomers of hydroxynaphthoic acid are separated by selective extraction o...
|
|
WO/1993/016029A1 |
Compounds of formula (1) wherein R1, R2, R3 and R4 independently are hydrogen, lower alkyl of 1 to 6 carbons, halogen or lower alkoxy of 1 to 6 carbons; R5 and R5' independently are hydrogen or lower alkyl of 1 to 6 carbons; Y is oxygen ...
|
|
WO/1993/015067A1 |
Benzopyran and other benzo-fused leukotriene B4 antagonists have formula (I) wherein R1 is a phenyl or substituted phenyl group, and A, n, R2 and R3 are as defined herein.
|
|
WO/1993/013045A1 |
The invention relates to a polymeric optical amplifier doped with lanthanide ions, which are present in the amplifier in the form of a complex. The invention also relates to novel electrically neutral lanthanide complexes which can be ap...
|
|
WO/1993/010791A1 |
The compound diflunisal (5-(2,4-difluorophenyl)-salicylic acid) of formula (I) is used for the production of a pharmaceutical composition for treatment of inflammatory and/or autoimmune diseases, such as psoriasis, Crohn\'s disease and u...
|
|
WO/1993/009074A2 |
Compounds having acidic protons and a molecular structure which can delocalize the electron density of the conjugate base (target compounds) are chlorinated by contacting such compounds with a perchloroalkane and aqueous base in the pres...
|
|
WO/1993/002036A1 |
A novel procedure for bromination of aromatic moieties utilizes N-bromosuccinimide or dibromodimethylhydantoin in an aqueous alkali medium. The bromination procedure is employed for the preparation of an intermediate used in the preparat...
|
|
WO/1993/002038A1 |
The invention relates to a method for preparing an ester composition in which at least one phenolic ether group of a molecule is reacted with at least one haloformyl group of another molecule. Preferably the molecules contain on average ...
|
|
WO/1992/021641A1 |
Certain dihydroxyindanone compounds, and their pharmaceutically-acceptable salts, are inhibitors of tyrosine kinase enzymes, and so are useful for the control of tyrosine kinase dependent diseases (e.g. cancer, atherosclerosis).
|
|
WO/1992/021644A1 |
This invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof wherein X is oxygen, sulfur, -CH=CH-, or -CH=N-; wherein R1 is -CO2R2 or tetrazole; wherein R2 is hydrogen, alkyl of 1 to 6 carbons or a p...
|
|
WO/1992/020643A1 |
Bi-aromatic compounds characterized in that they comply with general formula (I), where: R1 is -CH3, -CH2OH, -COR8, or -CH2OCOR9, R8 is H, OH, -OR10, -N(rr'), or alkyl, R10 is alkyl, alkenyl, aryl or aralkyl, r and r' being H, alkyl, ary...
|
|
WO/1992/019583A1 |
Aromatic bicyclic compounds of formula (I) where R1 is specifically -H, -CH3, -CH2OH, -OH, -CHO, -CONH2, -COOH, -COOalkyl, -SH, -S-alkyl, etc...; R2 is H; R3 is H, aryl, aralkyl or lower alkyl optionally substituted by a hydroxyl, a lowe...
|
|
WO/1992/017172A1 |
2,7-Disubstituted naphthalenes useful as leukotriene antagonists are disclosed herein.
|
|
WO/1992/012709A1 |
A composition for use in inhibiting cell infection by an enveloped virus, by administering to an infection site, a therapeutically effective amount of a macrocyclic compound composed of aryl ring subunits connected one to another by ring...
|
